A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Article information

Clin Mol Hepatol. 2022;28(3):478-480
Publication date (electronic) : 2022 June 16
doi : https://doi.org/10.3350/cmh.2022.0143
1Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea
2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
3Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea
Corresponding author : Won Kim Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea Tel: +82-2-870-2233, Fax: +82-2-831-2826, E-mail: drwon1@snu.ac.kr
Editor: Byoung Kuk Jang, Keimyung University School of Medicine, Korea
Received 2022 May 23; Accepted 2022 June 12.

Nonalcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide [1]. NAFLD comprises hepatic steatosis and nonalcoholic steatohepatitis (NASH), the latter of which irreversibly progresses to cirrhosis and hepatocellular carcinoma. Despite the gravity of NAFLD, efforts to develop effective pharmacological interventions have yet to achieve an approval of anti-NASH therapeutics [2]. Given that NAFLD is a hepatic manifestation of metabolic syndrome, the association of NAFLD with obesity and diabetes has been investigated to identify a novel therapeutic target for NAFLD. In this regard, it has been investigated whether different classes of anti-diabetic medications, such as thiazolidinediones, may also have an ability to ameliorate NAFLD [3,4].

Dipeptidyl peptidase-4 (DPP-4) is an enzyme that catalyzes the cleavage of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide. As incretin hormones stimulate insulin release and inhibit glucagon release, DPP-4 inhibitors have attracted attention as an effective option for diabetes without the risk of hypoglycemia [5]. Given that diabetes is a risk factor for NAFLD, and the circulating DPP-4 levels are increased in patients with NAFLD [6], it is reasonable to speculate that DPP-4 inhibitors might have a beneficial effect on NAFLD. Indeed, several papers have demonstrated that DPP-4 inhibitors attenuated steatosis in experimental NAFLD models [7-9]. However, underlying mechanisms by which DPP-4 inhibitors exert effects on NAFLD improvement remain obscure.

In this issue of Clinical and Molecular Hepatology, Oh et al. [10] conducted a study to identify the subgroup population among NAFLD patients who better respond to DPP-4 inhibitors and to verify the biomarkers that characterize the features of the responders. To first determine the benefit of DPP-4 inhibitors in the experimental NAFLD models, the authors performed a basket trial, and evogliptin was administered to different types of murine experimental NAFLD, including the high-fat diet (HFD)-induced, methionine choline-deficient diet (MCD)-induced, and Western-diet-induced models. Among the models chosen, evogliptin was shown to reduce the NAFLD activity score and fibrosis stage in HFD-fed mice.

Another important point addressed by Oh et al. [10] was that insulin-like growth factor-binding protein 1 (IGFBP1) could function as a biomarker to predict the efficacy of DPP-4 inhibitors. The authors demonstrated that hepatic expression of IGFBP1 prior to evogliptin treatment was higher in mice that better responded to evogliptin compared with non-responders. Intriguingly, the expression of IGFBP1 was lower in responders after the treatment with evogliptin, suggesting the correlation between the expression of IGFBP1 with the degree of NAFLD as well as diabetes. Indeed, IGFBP1 has been suggested to control blood glucose levels and maintain metabolic homeostasis [11,12]. Stanley et al. [13] reported that transcript levels of IGFBP1 were lower in individuals with higher steatosis grade and NAFLD activity scores. This is corroborated by the notions that IGFBP1 production is inhibited by insulin, and blood levels of IGFBP1 is inversely correlated with metabolic disease [14]. Given the aforementioned biological function of IGFBP1, it is presumed that IGFBP1 could work as a biomarker that predicts the efficacy of DPP-4 inhibitors against NAFLD.

Although Oh et al. [10] elegantly identified the probable biomarker for DPP-4 inhibitors, the current paper also revealed the limitation of the DPP-4-inhibiting approach for NASH treatment. Evogliptin failed to reduce the NAFLD activity score and fibrosis severity in the MCD-induced model and the Western-diet model, which better reflect NASH-associated liver injury, inflammation, and fibrosis than the HFD-induced model [15]. Indeed, 16-week HFD-feeding in mice promotes hepatic fat accumulation, but hardly induces the typical histological feature of NASH. Therefore, the current study provides an indirect evidence suggesting that evogliptin is not an effective option to pharmacologically treat the broad spectrum of NAFLD. In light of the correlation between the severity of metabolic liver diseases with that of diabetes, mild effect of evogliptin on NAFLD improvement could be in line with the lesser glucose-lowering ability of DPP-4 inhibitors than other classes of anti-diabetic medications, such as thiazolidinediones and GLP-1 receptor agonists.

In addition to evogliptin, there are several other DPP-4 inhibitors currently available in market for the treatment of diabetes, including sitagliptin, vildagliptin, linagliptin, and saxagliptin [16]. The study by Oh et al. [10] provided evidence that IGFBP1 is an evogliptin-specific biomarker; however, further studies are required to verify whether IGFBP1 can also function as the biomarker for other DPP-4 inhibitors in general. Successful completion of the study will lead to the identification of IGFBP1 as a class-specific biomarker for NAFLD treatment and accelerate the advent of the tailored application of DPP-4 inhibitors to medical treatments for NAFLD.


Authors’ contributions

SH drafted the manuscript. WK revised and finalized the manuscript.

Conflicts of Interest

The authors have no conflicts to disclose.


This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2021R1A2C2005820 and 2021M3A9E4021818).



dipeptidyl peptidase-4


glucagon-like peptide-1


high-fat diet


insulin-like growth factor-binding protein 1


methionine cholinedeficient diet


nonalcoholic fatty liver disease


nonalcoholic steatohepatitis


1. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond) 2018;18:245–250.
2. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908–922.
3. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017;66:180–190.
4. Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevila-Pico C, Liu IC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol 2018;16:558–566. e2.
5. Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne) 2019;10:389.
6. Barchetta I, Ceccarelli V, Cimini FA, Barone E, Sentinelli F, Coluzzi M, et al. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. J Endocrinol Invest 2021;44:979–988.
7. Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. Hepat Med 2018;10:23–31.
8. Kim MK, Chae YN, Ahn GJ, Shin CY, Choi SH, Yang EK, et al. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models. Arch Pharm Res 2017;40:268–281.
9. Nakamura K, Fukunishi S, Yokohama K, Ohama H, Tsuchimoto Y, Asai A, et al. A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. Int J Mol Med 2017;39:969–983.
10. Oh JH, Jun DW, Kim HY, Lee SM, Yoon EL, Hwang J, et al. Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial. Clin Mol Hepatol 2022;28:497–509.
11. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 1991;129:2254–2256.
12. Yki-Järvinen H, Mäkimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 1995;80:3227–3232.
13. Stanley TL, Fourman LT, Zheng I, McClure CM, Feldpausch MN, Torriani M, et al. Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2021;106:e520–e533.
14. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 2008;51:1135–1145.
15. Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, et al. Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis. Hepatology 2019;69:2241–2257.
16. Deacon CF. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab 2018;20 Suppl 1:34–46.

Article information Continued